Use of mometasone furoate for treating airway passage and lung disease

Abstract

The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.

1 - 29 . (canceled) 
   
   
       30 . A method of treating allergic, non-allergic and inflammatory diseases of the upper airway passages comprising administering once daily to nasal passages about 200 micrograms of mometasone furoate. 
   
   
       31 . The method of  claim 30 , wherein the corticosteroid responsive disease is at least one disease selected from the group consisting of seasonal allergic rhinitis, perennial rhinitis, non-malignant proliferative disease of the airway passage, inflammatory diseases of the airway passage and non-allergic rhinitis. 
   
   
       32 . The method of  claim 30 , wherein treating said corticosteroid responsive disease provides relief of at least one sign or symptom selected from the group consisting of seasonal or perennial sneezing, rhinorrhea, nasal congestion, pruritis, eye itching, redness, and tearing. 
   
   
       33 . The method of  claim 30 , wherein the disease is a non-malignant proliferative disease of the airway passage. 
   
   
       34 . The method of  claim 30 , wherein the mometasone furoate is administered as anhydrous mometasone furoate. 
   
   
       35 . The method of  claim 30 , wherein the mometasone furoate is administered in the form of an aqueous suspension of mometasone furoate monohydrate. 
   
   
       36 . The method of  claim 30 , wherein the mometasone furoate is administered in the form of an aqueous suspension of anhydrous mometasone furoate. 
   
   
       37 . The method of  claim 30 , wherein there are administered 200 micrograms of mometasone furoate by applying two times to each nostril about 50 micrograms of mometasone furoate. 
   
   
       38 . A method of treating allergic, non-allergic and inflammatory diseases of the upper airway passages comprising administering twice daily to nasal passages about 200 micrograms of mometasone furoate. 
   
   
       39 . The method of  claim 38 , wherein the mometasone furoate is administered in the form of an aqueous suspension. 
   
   
       40 . The method of  claim 38 , wherein the mometasone furoate is administered in the form of an aqueous suspension of mometasone furoate monohydrate. 
   
   
       41 . The method of  claim 38 , wherein the mometasone furoate is administered in the form of an aqueous suspension of anhydrous mometasone furoate. 
   
   
       42 . The method of  claim 38 , wherein there are administered 200 micrograms of mometasone furoate by applying two times to each nostril about 50 micrograms of mometasone furoate. 
   
   
       43 . The method of  claim 38 , wherein the corticosteroid responsive disease is at least one disease selected from the group consisting of seasonal allergic rhinitis, perennial rhinitis, non-malignant proliferative disease of the airway passage, inflammatory diseases of the airway passage and non-allergic rhinitis. 
   
   
       44 . The method of  claim 38 , wherein treating said corticosteroid responsive disease provides relief of at least one sign or symptom selected from the group consisting of seasonal or perennial sneezing, rhinorrhea, nasal congestion, pruritis, eye itching, redness, and tearing. 
   
   
       45 . The method of  claim 38 , wherein the disease is a non-malignant proliferative disease of the airway passage. 
   
   
       46 . A method of using a mometasone furoate formulation comprising administering twice daily to nasal passages about 200 micrograms of mometasone furoate. 
   
   
       47 . The method of  claim 46 , wherein the mometasone furoate is administered as anhydrous mometasone furoate. 
   
   
       48 . The method of  claim 46 , wherein the mometasone furoate is administered as mometasone furoate monohydrate. 
   
   
       49 . The method of  claim 46 , wherein there are administered 200 micrograms of mometasone furoate by applying two times to each nostril about 50 micrograms of mometasone furoate.